Nuformix PLC NXP004 patent application filing (1492S)
November 12 2021 - 2:00AM
UK Regulatory
TIDMNFX
RNS Number : 1492S
Nuformix PLC
12 November 2021
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
Nuformix plc
("Nuformix" or the "Company")
NXP004 patent application filing
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that it has filed a new patent application
in relation to NXP004.
This filing covers a new family of co-crystalline forms of an
undisclosed marketed drug that is approved globally for the
treatment of several cancers and that had global sales of over
GBP1bn in 2020. This is the second patent application related to
NXP004 that Nuformix has filed and it complements the previous
patent application on NXP004 co-crystals, thus expanding the
Company's intellectual property portfolio.
Anne Brindley, Chief Executive Officer, Nuformix, commented: "We
are pleased to have filed this new patent application for NXP004.
Data that we have generated on these new co-crystal forms in the
past six months has shown improvements over the marketed form that
justifies filing this new application. This application, if
granted, will strengthen the patent estate for NXP004 and
Nuformix's IP portfolio as a whole."
Enquiries:
Nuformix plc via Walbrook
Dr Alastair Riddell, Non-Executive
Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR nuformix@walbrookpr.com or +44 (0)20
7933 8780
Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 / +44
(0)7867 984 082
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLDLTLLLIL
(END) Dow Jones Newswires
November 12, 2021 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024